[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606035":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":10,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":10,"overallStatus":58,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":10},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ATTR-AS group",null,"Patients were grouped according to the presence or absence of ATTR, i.e., into the isolated AS group and the ATTR-AS group.",[13],"Procedure: transcatheter aortic valve replacement (TAVR)",{"label":15,"type":10,"description":11,"interventionNames":16},"AS group",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"PROCEDURE","transcatheter aortic valve replacement (TAVR)","TAVR is a minimally invasive cardiac interventional procedure that delivers a compressed artificial aortic valve to the diseased aortic valve site via peripheral blood vessels (e.g., the femoral artery) or the apex of the heart through a catheter, releases and deploys the valve to replace the original diseased valve leaflets, thereby restoring normal valve function and treating severe aortic stenosis (AS).",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Daxin Zhou","Fudan University","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Ming Li","CONTACT","13564254007","li.mingfei@zs-hospital.sh.cn",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Dan Tian","13916157135","tian.dan@zs-hospital.sh.cn",{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100606035","cardiac-amyloidosis-in-patients-with-aortic-stenosis-100606035",false,"NCT07170306","Cardiac Amyloidosis in Patients With Aortic Stenosis","A Study on the Prevalence and Clinical Characteristics of Cardiac Amyloidosis in Patients With Aortic Stenosis","Inclusion Criteria:\n\n* Male or female patients aged ≥ 65 years and ≤ 85 years;\n* Patients with moderate-to-severe degenerative aortic stenosis (AS) who are hospitalized and scheduled to undergo transcatheter aortic valve replacement (TAVR);\n* Patients who voluntarily sign the Informed Consent Form (ICF) and are able to comply with the study-specified treatment plan, follow-up visits, laboratory tests, and other requirements.\n\nExclusion Criteria:\n\n* Aortic stenosis (AS) caused by congenital diseases or rheumatic immune diseases;\n* Severe renal impairment, chronic dialysis, or unresolved acute kidney injury after transcatheter aortic valve replacement (TAVR);\n* Terminal-stage diseases with an expected life span of \\\u003C 6 months;\n* Participation in other ongoing investigational studies of drugs or medical devices that have not yet been completed;\n* Patients who are unable to attend the follow-up visits scheduled in the study;\n* Failure to undergo TAVR surgery, transfer to surgical treatment, or in-hospital death.","ALL","65 Years","85 Years",{"count":51,"type":52},143,"ESTIMATED","OBSERVATIONAL","This study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic stenosis (AS), compare the clinical characteristics between patients with isolated AS and those with AS complicated by CA (CA-AS), and simultaneously explore the impact of transcatheter aortic valve replacement (TAVR) on serum transthyretin (TTR) levels in patients with AS complicated by transthyretin amyloidosis (ATTR-AS), as well as its influence on the treatment outcomes of patients with isolated AS and ATTR-AS.",[56,57],"Aortic Stenosis","Transthyretin Amyloid Cardiomyopathy","NOT_YET_RECRUITING","2026-01-15",{"date":61,"type":62},"2026-01-20","ACTUAL",{"date":64,"type":52},"2026-01-31",{"date":66,"type":52},"2028-05-31",{"name":5,"class":6}]